We are pleased to announce that B · SYNC® ON has successfully received regulatory approval in a major market: the United States of America. This milestone represents a significant achievement for Galventa and a major step forward in our global expansion strategy.
Gaining market authorization in the USA reflects the strength of our scientific foundation and the quality standards that underpin every Galventa formulation. This market is known for its rigorous regulatory frameworks, and approval in it affirms B · SYNC® ON's credibility as a clinically validated nutraceutical solution.
With this approval in place, B · SYNC® ON can now reach consumers in one of the world's most dynamic health and wellness market. The USA represents one of the largest and most competitive nutraceutical markets globally. This opens a meaningful opportunity for distribution, partnerships, and brand growth.
This approval is the result of months of careful preparation and close collaboration with our regulatory and commercial partners. We are grateful to everyone involved in making it possible. Galventa remains committed to expanding access to our innovations responsibly and in full compliance with local regulatory standards. We look forward to building on this momentum as we continue our international growth journey.
